Received Jun 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
prurigo nodularis developed after the covid vaccine; This is a spontaneous report received from a Consumer or other non HCP from License Party. Other Case identifier(s): 2025SA153013 (Sanofi). A 62-year-old female patient (unknown if pregnant) received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPIXENT), since 12Dec2022 (Lot number: 4F595A, Expiration Date: 30Nov2026) at 300 mg (300 mg qow), subcutaneous for dermatitis atopic. The patient's relevant medical history included: "atopic dermatitis" (ongoing). Concomitant medication(s) included: CALCIPOTRIENE; SULFACETAMIDE SODIUM AND SULFUR [SULFACETAMIDE SODIUM;SULFUR]; NALTREXONE HCL. The following information was reported: NEURODERMATITIS (non-serious), outcome "unknown", described as "prurigo nodularis developed after the covid vaccine". The action taken for dupilumab was unknown. Additional information: It was reported patient said that when she was taking dupixent she formed abscesses more than once and the medication was not working. Patient had been started on nemluvio therapy. patient stated prurigo nodularis developed after the covid vaccine. no other details were provided'. An unknown (nemluvio therapy) corrective treatment was received for abscess and not reported for neurodermatitis." Batch/lot number is not provided, and it cannot be obtained. BNT162B2 OMICRON (KP.2) is under agreement with BIONTECH SE.
Atopic dermatitis
CALCIPOTRIENE; SULFACETAMIDE SODIUM AND SULFUR [SULFACETAMIDE SODIUM;SULFUR]; NALTREXONE HCL; DUPIXENT